Kolon Life Science: "TG-C Mixed Cell Gene Therapy Secures Asian Patents"
Kolon Life Science announced on April 2 that its affiliate, Kolon TissueGene, has recently secured a series of patent registrations for the "mixed cell gene therapy" of TG-C, an osteoarthritis gene therapy under development, in several Asian countries.
This patent covers the "mixed cell gene therapy" technology, which involves administering both cells engineered to produce growth factors (TGF-β or BMP) and cells that respond to these signals to exert therapeutic effects. TG-C is administered by combining two solutions: one containing chondrocytes and the other containing genetically modified cells.
The Asian regional patent was granted in the Philippines and Malaysia last month, following Indonesia in February this year. Kolon Life Science is responsible for local development and commercialization of TG-C in Asia.
According to the company, TG-C is currently in the final stages of a Phase 3 clinical trial for knee osteoarthritis in the United States. Kolon TissueGene, which is conducting the U.S. clinical trial for TG-C, aims to release topline results in July, after completing two years of follow-up and data analysis. Based on this, the company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of next year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Hankook, CEO of Kolon Life Science, stated, "This patent registration is significant as it concretizes the rights to the core design and technology of TG-C mixed cell gene therapy in major Asian markets," adding, "We will accelerate preparations for local development and commercialization going forward."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.